Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji has been Chairman of Scilex from March 2019 to August 2023 and served as the CEO of Scilex Pharmaceuticals from November 2016 to March 2019.
Dr. Ji co-founded Sorrento Therapeutics, Inc. and has served as a director since 2006, as its CEO and President since September 2012, and as Chairman of its board of directors since 2017.
During his tenure at Sorrento, he has engineered and led a phenomenal growth of Sorrento through acquisition and mergers including Bioserv, Scilex Pharmaceuticals, Concortis Biotherapeutics, Levena Biopharma, LACEL, TNK Therapeutics, Virttu Biologics, Ark Animal Health and Sofusa Lymphatic Delivery Systems. Dr. Ji has served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim CEO from April 2011 to September 2012.
Prior to Sorrento, he held senior executive positions at CombiMatrix, Stratagene, co-founded Stratagene Genomics, a subsidiary of Stratagene, and served as its President & CEO and a member of the board of directors. Henry Ji received a doctorate from the University of Minnesota and an undergraduate degree from Fudan University.